(2R)-3-methyl-2-[N-({4-[2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoic acid

• ChemBase编号: 69138
• 分子式: C24H29N5O3
• 平均质量: 435.51876
• 单一同位素质量: 435.22703981
• SMILES: C(=O)([C@@H](C(C)C)N(C(=O)CCCC)Cc1ccc(cc1)c1c(cccc1)c1[nH]nnn1)O
• Canonical SMILES: CCCCC(=O)N([C@@H](C(=O)O)C(C)C)Cc1ccc(cc1)c1ccccc1c1nnn[nH]1
• InChI: InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m1/s1
• InChIKey: ACWBQPMHZXGDFX-JOCHJYFZSA-N

名称和登记号

名称

• IUPAC标准名: (2R)-3-methyl-2-[N-({4-[2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoic acid
• IUPAC传统名: (2R)-3-methyl-2-[N-({4-[2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoic acid
• 别名: N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-D-valine; CGP 49309; ent-Valsartan; D-Valsartan; (R)-2-(N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid; N-(1-Oxopentyl)-N-[[2’-(1H-tetrazol-5-yl)[1,1’-biphenyl]-4-yl]methyl]-L-valine; CGP 48933; Diovan; Nisis; Tareg; Valsartan

登记号

• CAS号: 137862-53-4; 137862-87-4
• MDL号: MFCD18252868
• PubChem SID: 162034867
• PubChem CID: 5284633

理论计算性质

• Acid pKa: 3.9951215
• 质子受体: 6
• 质子供体: 2
• LogD (pH = 5.5): 2.3063507
• LogD (pH = 7.4): 0.08263492
• Log P: 4.5932384
• 摩尔折射率: 134.7733 cm^3
• 极化性: 48.58226 Å^3
• 极化表面积: 112.07 Å^2
• 可自由旋转的化学键: 10
• 里宾斯基五规则: true

分子性质

理化性质

• 溶解度: Chloroform; Ethanol; Methanol
• 外观: White Solid; White to Off-White Solid
• 熔点: 108-110°C; 83-88°C

安全信息

• 保存条件: -20°C Freezer, Under inert atmosphere; Refrigerator
• 保存注意事项: Hygroscopic; IRRITANT
• TSCA收录: false

产品相关信息

• 纯度: 95+%

详细说明

Toronto Research Chemicals - V095750

A nonpeptide angiotensin II AT1-receptor antagonist. Antihypertensive.

Toronto Research Chemicals - V095755

ent-Valsartan is the (R)-enantiomer of Valsartan (V095750).

参考文献

• Criscione, L., et al.: Brit. J. Pharmacol., 110, 761 (1993)
• Muller, P., et al.: Eur. J. Clin. Pharmacol., 47, 231 (1994)
• Corea, L., et al.: Clin. Pharmacol. Ther., 60, 341 (1996)
• Satana, E;., et al.: J. Pharm. Biomed. Anal., 25, 1009 (1996)
• Sironi, L., et al.: Hypertension, 37, 961 (1996)